Cancer of unknown primary origin pathophysiology: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}}, {{RAK}} | {{CMG}}; {{AE}}, {{RAK}} | ||
==Overview== | ==Overview== | ||
The exact [[pathogenesis]] of cancer of unknown primary origin is not fully understood. Several studies noted consistency between metastatic cancer of unknown primary and metastases with known primary origins based on chromosomal | The exact [[pathogenesis]] of cancer of unknown primary origin is not fully understood. Several [[Evidence|studies]] noted consistency between [[metastatic cancer]] of unknown primary and metastases with known primary origins based on [[Chromosomal abnormalities|chromosomal abnormalitie]]<nowiki/>s and overexpression of several [[genes]]. | ||
| Line 10: | Line 10: | ||
===Pathogenesis=== | ===Pathogenesis=== | ||
*The exact [[pathogenesis]] of cancer of unknown primary origin is not fully understood. | *The exact [[pathogenesis]] of cancer of unknown primary origin is not fully understood. | ||
*Cancer of unknown primary, like other cancers, arises from one cell that has managed to escape regulation and produces a tumor at a certain site (the site of origin) and consequently metastasizes to other parts of the body. | *Cancer of unknown primary, like other cancers, arises from one [[cell]] that has managed to escape regulation and produces a [[tumor]] at a certain site (the site of origin) and consequently metastasizes to other parts of the body. | ||
*It is thought that the site of origin of CUP remains unknown due to one or more of the following theories:<ref name="pmid19262901" /> | *It is thought that the site of origin of CUP remains unknown due to one or more of the following theories:<ref name="pmid19262901" /> | ||
**Remaining small and undetectable clinically | **Remaining small and undetectable clinically | ||
| Line 21: | Line 21: | ||
The factors that keep the primary site of CUP hidden have not yet been identified. | The factors that keep the primary site of CUP hidden have not yet been identified. | ||
Several studies noted consistency between metastatic cancer of unknown primary and metastases with known primary origins based on chromosomal abnormalities and overexpression of several genes including: | Several studies noted consistency between metastatic cancer of unknown primary and metastases with known primary origins based on [[chromosomal abnormalities]] and overexpression of several [[genes]] including: | ||
* Bcl2<ref name="pmid9677443">{{cite journal| author=Briasoulis E, Tsokos M, Fountzilas G, Bafaloukos D, Kosmidis P, Samantas E et al.| title=Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. | journal=Anticancer Res | year= 1998 | volume= 18 | issue= 3B | pages= 1907-14 | pmid=9677443 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9677443 }}</ref> | *[[Bcl-2|Bcl2]]<ref name="pmid9677443">{{cite journal| author=Briasoulis E, Tsokos M, Fountzilas G, Bafaloukos D, Kosmidis P, Samantas E et al.| title=Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. | journal=Anticancer Res | year= 1998 | volume= 18 | issue= 3B | pages= 1907-14 | pmid=9677443 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9677443 }}</ref> | ||
** Bcl-2 expression was seen in 65% of tumors | ** Bcl-2 expression was seen in 65% of tumors | ||
** It was found to be overexpressed in 40% of tumors | ** It was found to be overexpressed in 40% of tumors | ||
* p53<ref name="pmid9677443" /> | *[[p53]]<ref name="pmid9677443" /> | ||
** Expression of p53 was detected in 70.2% of tumors | ** Expression of p53 was detected in 70.2% of tumors | ||
** It was found to be overexpressed in 53% of tumors | ** It was found to be overexpressed in 53% of tumors | ||
* C-myc<ref name="pmid8669824" /> | *[[C-myc]]<ref name="pmid8669824" /> | ||
** 96% of the tumors studied showed positive immunoreactivity for c-myc | ** 96% of the tumors studied showed positive immunoreactivity for c-myc | ||
* Ras<ref name="pmid8669824">{{cite journal| author=Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N| title=Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. | journal=Anticancer Res | year= 1995 | volume= 15 | issue= 6B | pages= 2563-7 | pmid=8669824 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8669824 }}</ref> | *[[Ras]]<ref name="pmid8669824">{{cite journal| author=Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N| title=Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. | journal=Anticancer Res | year= 1995 | volume= 15 | issue= 6B | pages= 2563-7 | pmid=8669824 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8669824 }}</ref> | ||
** 92% of the tumors studied showed positive immunoreactivity for Ras | ** 92% of the tumors studied showed positive immunoreactivity for Ras | ||
* C-erbB-2<ref name="pmid8669824" /> | *[[ErbB|C-erbB-2]]<ref name="pmid8669824" /> | ||
** 65% of the tumors studied showed positive immunoreactivity for c-erbB-2 | ** 65% of the tumors studied showed positive immunoreactivity for c-erbB-2 | ||
Latest revision as of 15:55, 16 October 2019
|
Cancer of unknown primary origin Microchapters |
|
Differentiating Cancer of Unknown Primary Origin from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cancer of unknown primary origin pathophysiology On the Web |
|
American Roentgen Ray Society Images of Cancer of unknown primary origin pathophysiology |
|
Cancer of unknown primary origin pathophysiology in the news |
|
Risk calculators and risk factors for Cancer of unknown primary origin pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: , Roukoz A. Karam, M.D.[2]
Overview
The exact pathogenesis of cancer of unknown primary origin is not fully understood. Several studies noted consistency between metastatic cancer of unknown primary and metastases with known primary origins based on chromosomal abnormalities and overexpression of several genes.
Pathophysiology
Pathogenesis
- The exact pathogenesis of cancer of unknown primary origin is not fully understood.
- Cancer of unknown primary, like other cancers, arises from one cell that has managed to escape regulation and produces a tumor at a certain site (the site of origin) and consequently metastasizes to other parts of the body.
- It is thought that the site of origin of CUP remains unknown due to one or more of the following theories:[1]
- Remaining small and undetectable clinically
- Disappearing after metastasizing
- Elimination by body's defense
- It remains unknown whether cancers of unknown primaries are genetically or phenotypically distinct from metastasis with known origins.[1]
Genetics
The factors that keep the primary site of CUP hidden have not yet been identified.
Several studies noted consistency between metastatic cancer of unknown primary and metastases with known primary origins based on chromosomal abnormalities and overexpression of several genes including:
- Bcl2[2]
- Bcl-2 expression was seen in 65% of tumors
- It was found to be overexpressed in 40% of tumors
- p53[2]
- Expression of p53 was detected in 70.2% of tumors
- It was found to be overexpressed in 53% of tumors
- C-myc[3]
- 96% of the tumors studied showed positive immunoreactivity for c-myc
- Ras[3]
- 92% of the tumors studied showed positive immunoreactivity for Ras
- C-erbB-2[3]
- 65% of the tumors studied showed positive immunoreactivity for c-erbB-2
References
- ↑ 1.0 1.1 Varadhachary GR (2007). "Carcinoma of unknown primary origin". Gastrointest Cancer Res. 1 (6): 229–35. PMC 2631214. PMID 19262901.
- ↑ 2.0 2.1 Briasoulis E, Tsokos M, Fountzilas G, Bafaloukos D, Kosmidis P, Samantas E; et al. (1998). "Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study". Anticancer Res. 18 (3B): 1907–14. PMID 9677443.
- ↑ 3.0 3.1 3.2 Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N (1995). "Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin". Anticancer Res. 15 (6B): 2563–7. PMID 8669824.